|
|
|
|
| Advertisement |
OUTSIDE OF US & CANADA
The Changing Biopharma Risk Equation: Written by The Economist Intelligence Unit, this paper incorporates the results of a survey of 254 pharmaceutical executives worldwide and a range of interviews with industry experts, explores global pharmaceutical companies' growth strategies and their plans for managing the associated risks. Sponsored by Merck.  Download this White Paper Now
|
|
| Advertisement |
Podcast: Assuring Trust in the Digital Space
Pharm Exec talks to Mollie Shields-Uehling, a leading advocate for high-assurance identity trust for cyber-transactions in the biopharmaceutical industry. Listen to the podcast for a timely, 15-minute discussion covering topics like cyber/technical security; eHealth regulatory compliance; work flow automation, the benefits of eSignature programs, and collaboration around key aspects of drug development like the administration of clinical trials and research partnering.
 Click here to listen |
|
|
| Strategy |
 |
|
The Rise of the CFO Strategist |
The role of the biopharma chief financial officer is ever-evolving. "Jack of all, master of none" doesn't cut it. Mastery of far more than the company's balance sheet is a necessity, writes Casey McDonald
... /Read more/ |
|
|
| Advertisement |
Achieving Success in the Biosimilar Market
Live Webinar: Wednesday, October 19 at 2 PM EDT
 Register now |
|
|
| Event |
| Advertisement |
Supporting internal and external decision-making through effective MSL activities
Live Webinar: Tuesday 18th October, 11:00am EDT
 Register now |
|
|
|
ADVERTISEMENT
|
| Advertisement |
Technology can't replace people- why Patient Support Programs need a personal approach
On Demand
 Learn more |
|
|
| Advertisement |
Optimizing real-world evidence programs to generate value
Tailored approaches for emerging biopharma
On Demand
 Learn more |
|
|
| Industry update |
| //Reata Pharmaceuticals (Irving, TX) announced the appointment of Dawn Carter Bir as Vice President and Chief Commercial Officer.//Advaxis (Princeton, NJ) named Christopher Duke as Senior Vice President and Chief Operating Officer. //Chiasma (Waltham, MA), appojnted Mark J. Fitzpatrick as President and Chief Executive Officer.//Retrophin (San Diego, CA) announced that Alvin Shih, M.D., will be stepping down from his position as Executive Vice President and Head of Research and Development to become CEO of a start-up biotechnology company. Dr. Shih will remain in his current role until October 31, 2016 and has agreed to serve as a consultant to Retrophin thereafter.// |
|
|
